We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
Read MoreHide Full Article
Key Takeaways
OPKO Health secured $125 million in senior notes backed by mazdutide royalty interests.
The financing provides non-dilutive capital, with total payments capped at 1.5 times the funded amount.
OPKO Health retains future royalty economics after the payment cap, preserving longer-term upside.
OPKO Health (OPK - Free Report) expanded its strategic financing relationship with HealthCare Royalty (HCRx) by issuing $125 million of senior secured notes backed by its royalty interests from the mazdutide license agreement with Eli Lilly. The transaction provides OPKO with additional non-dilutive capital while allowing it to retain meaningful long-term participation in the drug’s royalty potential.
From an investor perspective, the deal strengthens OPKO’s financial flexibility without issuing equity, while monetizing a portion of the value of an emerging royalty stream. The financing is particularly encouraging given mazdutide’s growth opportunity in China, although the company has capped near-term royalty proceeds through the financing structure. OPKO will retain future royalty economics after payments reach 1.5 times the funded amount, preserving longer-term upside from the franchise.
Likely Trend of OPK Stock Following the News
Shares of OPK have traded flat since the announcement on Aug. 13. In the year-to-date period, shares of the company have gained 7.9% against the industry’s 8.1% decline. The S&P 500 increased 13.2% in the same time frame.
The financing could support OPKO Health’s long-term business by improving its liquidity and financial flexibility without diluting existing shareholders. By monetizing a portion of its expected mazdutide royalties, OPKO can access capital today while retaining meaningful exposure to the drug’s future commercial success. The additional liquidity could provide greater flexibility to fund operations, advance its pipeline, pursue strategic investments or reduce reliance on more dilutive financing alternatives.
OPK currently has a market capitalization of $1.02 billion.
Image Source: Zacks Investment Research
More on the News
Under the expanded financing arrangement, OPKO Health issued an additional $125 million in aggregate principal amount of senior secured notes to HealthCare Royalty, a business of KKR. The notes are secured by OPKO’s royalty interests arising from its mazdutide licensing agreement with Eli Lilly and are scheduled to mature in 2044, in line with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.
The transaction is structured to provide non-dilutive capital while allowing OPKO to unlock the value of a portion of its future royalty stream. Total payments under the expanded financing structure are capped at 1.5 times the amount funded, after which OPKO will retain the future royalty economics associated with the financed stream. This structure enables the company to monetize an emerging asset while maintaining exposure to its longer-term growth potential.
Mazdutide is being commercialized in China by Innovent Biologics under OPKO’s licensing arrangement with Eli Lilly, with OPKO entitled to royalties on commercial sales. The company recorded its initial mazdutide royalty revenues in 2025 following the product’s commercial launch activities in China. OPKO’s management highlighted the transaction as an example of its ability to leverage royalty-generating assets to secure financing while preserving shareholder value.
HCRx, which is majority owned by KKR and has committed more than $7 billion across more than 110 biopharmaceutical products since its founding in 2006, also views mazdutide as an attractive opportunity given its exposure to the high-growth Chinese market. The expanded relationship underscores the attractiveness of OPKO’s royalty portfolio as a source of alternative capital and further strengthens its financial partnership with HCRx.
A Recent Development by OPK
Recently, OPK reported a second-quarter 2026 loss of 1 cent per share, narrower than the year-ago quarter's loss of 19 cents. The figure beat the Zacks Consensus Estimate of a loss of 8 cents by 87.5%.
Revenues rose 4.3% year over year to $163.5 million, driven by strong growth in the Pharmaceuticals segment. The top line also surpassed the Zacks Consensus Estimate by 24.7%.
The better-than-expected performance reflected higher pharmaceutical revenues, including income related to the amended Nicoya licensing agreement, partially offset by lower Diagnostics revenues following last year's oncology asset divestiture.
OPK’s Zacks Rank & Key Picks
Currently, OPK carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.
View the Zacks #1 Rank List
Image: Bigstock
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
Key Takeaways
OPKO Health (OPK - Free Report) expanded its strategic financing relationship with HealthCare Royalty (HCRx) by issuing $125 million of senior secured notes backed by its royalty interests from the mazdutide license agreement with Eli Lilly. The transaction provides OPKO with additional non-dilutive capital while allowing it to retain meaningful long-term participation in the drug’s royalty potential.
From an investor perspective, the deal strengthens OPKO’s financial flexibility without issuing equity, while monetizing a portion of the value of an emerging royalty stream. The financing is particularly encouraging given mazdutide’s growth opportunity in China, although the company has capped near-term royalty proceeds through the financing structure. OPKO will retain future royalty economics after payments reach 1.5 times the funded amount, preserving longer-term upside from the franchise.
Likely Trend of OPK Stock Following the News
Shares of OPK have traded flat since the announcement on Aug. 13. In the year-to-date period, shares of the company have gained 7.9% against the industry’s 8.1% decline. The S&P 500 increased 13.2% in the same time frame.
The financing could support OPKO Health’s long-term business by improving its liquidity and financial flexibility without diluting existing shareholders. By monetizing a portion of its expected mazdutide royalties, OPKO can access capital today while retaining meaningful exposure to the drug’s future commercial success. The additional liquidity could provide greater flexibility to fund operations, advance its pipeline, pursue strategic investments or reduce reliance on more dilutive financing alternatives.
OPK currently has a market capitalization of $1.02 billion.
Image Source: Zacks Investment Research
More on the News
Under the expanded financing arrangement, OPKO Health issued an additional $125 million in aggregate principal amount of senior secured notes to HealthCare Royalty, a business of KKR. The notes are secured by OPKO’s royalty interests arising from its mazdutide licensing agreement with Eli Lilly and are scheduled to mature in 2044, in line with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement.
The transaction is structured to provide non-dilutive capital while allowing OPKO to unlock the value of a portion of its future royalty stream. Total payments under the expanded financing structure are capped at 1.5 times the amount funded, after which OPKO will retain the future royalty economics associated with the financed stream. This structure enables the company to monetize an emerging asset while maintaining exposure to its longer-term growth potential.
Mazdutide is being commercialized in China by Innovent Biologics under OPKO’s licensing arrangement with Eli Lilly, with OPKO entitled to royalties on commercial sales. The company recorded its initial mazdutide royalty revenues in 2025 following the product’s commercial launch activities in China. OPKO’s management highlighted the transaction as an example of its ability to leverage royalty-generating assets to secure financing while preserving shareholder value.
HCRx, which is majority owned by KKR and has committed more than $7 billion across more than 110 biopharmaceutical products since its founding in 2006, also views mazdutide as an attractive opportunity given its exposure to the high-growth Chinese market. The expanded relationship underscores the attractiveness of OPKO’s royalty portfolio as a source of alternative capital and further strengthens its financial partnership with HCRx.
A Recent Development by OPK
Recently, OPK reported a second-quarter 2026 loss of 1 cent per share, narrower than the year-ago quarter's loss of 19 cents. The figure beat the Zacks Consensus Estimate of a loss of 8 cents by 87.5%.
Revenues rose 4.3% year over year to $163.5 million, driven by strong growth in the Pharmaceuticals segment. The top line also surpassed the Zacks Consensus Estimate by 24.7%.
The better-than-expected performance reflected higher pharmaceutical revenues, including income related to the amended Nicoya licensing agreement, partially offset by lower Diagnostics revenues following last year's oncology asset divestiture.
OPK’s Zacks Rank & Key Picks
Currently, OPK carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are McKesson (MCK - Free Report) , Phibro Animal Health (PAHC - Free Report) and Cardinal Health (CAH - Free Report) .
McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period.
Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%.
Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period.
Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%.
Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period.